183 related articles for article (PubMed ID: 36907773)
1. Inhibition of PIM Kinases Promotes Neuroblastoma Cell Differentiation to a Neuronal Phenotype.
Julson JR; Quinn CH; Bownes LV; Hutchins SC; Stewart JE; Aye J; Yoon KJ; Beierle EA
J Pediatr Surg; 2023 Jun; 58(6):1155-1163. PubMed ID: 36907773
[TBL] [Abstract][Full Text] [Related]
2. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
Brunen D; de Vries RC; Lieftink C; Beijersbergen RL; Bernards R
Mol Cancer Ther; 2018 Apr; 17(4):849-857. PubMed ID: 29440296
[TBL] [Abstract][Full Text] [Related]
3. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin.
Julson JR; Quinn CH; Nazam N; Bownes LV; Stewart JE; Beierle EA
J Pediatr Surg; 2024 Mar; ():. PubMed ID: 38570263
[TBL] [Abstract][Full Text] [Related]
4. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
5. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
6. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
7. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
Yadav AK; Kumar V; Bailey DB; Jang BC
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
[TBL] [Abstract][Full Text] [Related]
8. Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells.
Lee M; Lee KH; Min A; Kim J; Kim S; Jang H; Lim JM; Kim SH; Ha DH; Jeong WJ; Suh KJ; Yang YW; Kim TY; Oh DY; Bang YJ; Im SA
Cancer Res Treat; 2019 Apr; 51(2):451-463. PubMed ID: 29879757
[TBL] [Abstract][Full Text] [Related]
9. New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations.
Marques MB; González-Durruthy M; da Silva Nornberg BF; Oliveira BR; Almeida DV; de Souza Votto AP; Marins LF
Curr Top Med Chem; 2019; 19(11):914-926. PubMed ID: 31072293
[TBL] [Abstract][Full Text] [Related]
10. Insights into the Interaction Mechanisms of the Proviral Integration Site of Moloney Murine Leukemia Virus (Pim) Kinases with Pan-Pim Inhibitors PIM447 and AZD1208: A Molecular Dynamics Simulation and MM/GBSA Calculation Study.
Chen Q; Wang Y; Shi S; Li K; Zhang L; Gao J
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671637
[TBL] [Abstract][Full Text] [Related]
11. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
[TBL] [Abstract][Full Text] [Related]
12. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
13. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
[TBL] [Abstract][Full Text] [Related]
14. Novel second-generation rexinoid induces growth arrest and reduces cancer cell stemness in human neuroblastoma patient-derived xenografts.
Marayati R; Bownes LV; Quinn CH; Wadhwani N; Williams AP; Markert HR; Atigadda V; Aye JM; Stewart JE; Yoon KJ; Beierle EA
J Pediatr Surg; 2021 Jun; 56(6):1165-1173. PubMed ID: 33762121
[TBL] [Abstract][Full Text] [Related]
15. PIM kinases 1, 2 and 3 in intracellular LIF signaling, proliferation and apoptosis in trophoblastic cells.
Mary Photini S; Chaiwangyen W; Weber M; Al-Kawlani B; Favaro RR; Jeschke U; Schleussner E; Morales-Prieto DM; Markert UR
Exp Cell Res; 2017 Oct; 359(1):275-283. PubMed ID: 28729093
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
17. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
Keeton EK; McEachern K; Dillman KS; Palakurthi S; Cao Y; Grondine MR; Kaur S; Wang S; Chen Y; Wu A; Shen M; Gibbons FD; Lamb ML; Zheng X; Stone RM; Deangelo DJ; Platanias LC; Dakin LA; Chen H; Lyne PD; Huszar D
Blood; 2014 Feb; 123(6):905-13. PubMed ID: 24363397
[TBL] [Abstract][Full Text] [Related]
18. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
[TBL] [Abstract][Full Text] [Related]
19. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
[TBL] [Abstract][Full Text] [Related]
20. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
Chen LS; Yang JY; Liang H; Cortes JE; Gandhi V
Leuk Lymphoma; 2016 Dec; 57(12):2863-2873. PubMed ID: 27054578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
